Epstein–Barr virus latent membrane protein 2 peptide–MHC complex (EBV LMP2 pMHC)

The Epstein–Barr virus (EBV) latent membrane protein 2 (LMP2) peptide–MHC complex is a specialized immunological target formed when EBV-infected cells process the viral LMP2 protein and present its peptide fragments on the cell surface via Major Histocompatibility Complex (MHC) molecules. LMP2 is a key viral protein expressed during EBV latency, particularly in Type II and Type III latency programs, which are associated with various malignancies such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease (PTLD). The complex, often involving the HLA-A*02:01 allele and the immunodominant CLGGLLTMV peptide, serves as the primary recognition site for cytotoxic T lymphocytes (CTLs) to identify and destroy EBV-harboring cells. In therapeutic contexts, this complex is targeted by adoptive T-cell therapies, such as tabelecleucel and posoleucel, which utilize donor-derived or engineered T cells to restore anti-viral immunity. Additionally, therapeutic vaccines and TCR-like antibodies are being developed to enhance the immune system's ability to detect these specific pMHC signatures on tumor cells. Because LMP2 is essential for maintaining viral latency and is selectively expressed in EBV-driven cancers, it represents a high-precision target for immunotherapy with minimal impact on healthy, non-infected tissues.

Other names

EBV LMP2 peptide-HLA complexLMP2 pMHCLMP2A peptide-MHC complexLMP2B peptide-MHC complexHLA-A*02:01/LMP2(426-434) complexLMP2-HLA complex

Adoptive T-cell transfer, active immunization, and T-cell receptor (TCR) mediated cytotoxicity targeting the viral peptide presented on MHC.